User login
Key clinical point: Patients with psoriatic arthritis (PsA) showed improvements in enthesitis scores on receiving 15 mg upadacitinib for 24 weeks, with the improvements being maintained for ≤56 weeks.
Major finding: At week 24, a significantly higher proportion of patients achieved a greater improvement in the Leeds Enthesitis Index (LEI) score with 15 mg upadacitinib vs placebo (59.8% vs 38.0%; P < .001), with the improvements being maintained by >65% of patients receiving upadacitinib at week 56. Among patients who achieved resolution (LEI = 0) at week 24, >80% did not have recurrent enthesitis with upadacitinib at week 56.
Study details: This post hoc analysis of the SELECT-PsA 1 and SELECT-PsA 2 trials analyzed the data of patients with PsA who received 15 mg upadacitinib (n = 639) or placebo (n = 635).
Disclosures: This study was funded by AbbVie. Five authors declared being employees of or holding stocks or stock options with AbbVie. Two authors declared receiving consulting fees from or having other ties with various sources, including AbbVie. Fabrizio Cantini declared no conflicts of interest.
Source: Cantini F, Marchesoni A, Novelli L, et al. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: A post hoc analysis of SELECT-PsA 1 and 2. Rheumatology (Oxford). 2024 (Feb 8). doi: 10.1093/rheumatology/keae057 Source
Key clinical point: Patients with psoriatic arthritis (PsA) showed improvements in enthesitis scores on receiving 15 mg upadacitinib for 24 weeks, with the improvements being maintained for ≤56 weeks.
Major finding: At week 24, a significantly higher proportion of patients achieved a greater improvement in the Leeds Enthesitis Index (LEI) score with 15 mg upadacitinib vs placebo (59.8% vs 38.0%; P < .001), with the improvements being maintained by >65% of patients receiving upadacitinib at week 56. Among patients who achieved resolution (LEI = 0) at week 24, >80% did not have recurrent enthesitis with upadacitinib at week 56.
Study details: This post hoc analysis of the SELECT-PsA 1 and SELECT-PsA 2 trials analyzed the data of patients with PsA who received 15 mg upadacitinib (n = 639) or placebo (n = 635).
Disclosures: This study was funded by AbbVie. Five authors declared being employees of or holding stocks or stock options with AbbVie. Two authors declared receiving consulting fees from or having other ties with various sources, including AbbVie. Fabrizio Cantini declared no conflicts of interest.
Source: Cantini F, Marchesoni A, Novelli L, et al. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: A post hoc analysis of SELECT-PsA 1 and 2. Rheumatology (Oxford). 2024 (Feb 8). doi: 10.1093/rheumatology/keae057 Source
Key clinical point: Patients with psoriatic arthritis (PsA) showed improvements in enthesitis scores on receiving 15 mg upadacitinib for 24 weeks, with the improvements being maintained for ≤56 weeks.
Major finding: At week 24, a significantly higher proportion of patients achieved a greater improvement in the Leeds Enthesitis Index (LEI) score with 15 mg upadacitinib vs placebo (59.8% vs 38.0%; P < .001), with the improvements being maintained by >65% of patients receiving upadacitinib at week 56. Among patients who achieved resolution (LEI = 0) at week 24, >80% did not have recurrent enthesitis with upadacitinib at week 56.
Study details: This post hoc analysis of the SELECT-PsA 1 and SELECT-PsA 2 trials analyzed the data of patients with PsA who received 15 mg upadacitinib (n = 639) or placebo (n = 635).
Disclosures: This study was funded by AbbVie. Five authors declared being employees of or holding stocks or stock options with AbbVie. Two authors declared receiving consulting fees from or having other ties with various sources, including AbbVie. Fabrizio Cantini declared no conflicts of interest.
Source: Cantini F, Marchesoni A, Novelli L, et al. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: A post hoc analysis of SELECT-PsA 1 and 2. Rheumatology (Oxford). 2024 (Feb 8). doi: 10.1093/rheumatology/keae057 Source